Related by context. All words. (Click for frequent words.) 86 randomized trials 82 randomized clinical trials 78 RCTs 77 meta analysis 77 randomized controlled trial 76 meta analyzes 75 placebo controlled trials 74 randomized controlled clinical trials 73 placebo controlled studies 73 observational studies 70 randomized controlled 70 randomized clinical 70 randomized controlled trials RCTs 69 trials RCTs 67 epidemiologic studies 67 epidemiological studies 66 observational study 65 placebo controlled clinical trials 65 randomized 64 randomized placebo controlled 64 nonrandomized 64 subgroup analyzes 63 prospective randomized 63 multicenter trials 63 longitudinal studies 63 prospective cohort 63 multicenter 63 placebo controlled 63 metaanalysis 62 double blinded randomized 62 multicenter study 62 Meta analyzes 62 prospective observational 62 prospective randomized controlled 61 randomized controlled clinical 61 calcium supplementation 61 prospective observational studies 61 antihypertensive therapy 61 placebo controlled clinical 60 vitamin D supplementation 60 lipid lowering therapy 60 ALLHAT 60 multicenter randomized 60 Cochrane reviewers 60 double blind placebo 60 postmenopausal women 59 UKPDS 59 Observational studies 59 HORIZONS AMI trial 59 Subgroup analyzes 59 prospective longitudinal 59 HCV SPRINT 59 retrospective cohort 59 pharmacological interventions 59 antioxidant supplementation 59 substudy 59 Randomized trials 59 Cochrane Systematic Review 59 topical NSAIDs 59 antioxidant supplements 58 DAPT 58 liver transplant recipients 58 thromboprophylaxis 58 RE LY 58 selenium supplementation 58 blinded randomized controlled 58 randomized blinded 58 randomized multicenter trial 58 infantile colic 58 multicentre 58 RE LY ® 58 active comparator 58 Cochrane Database 58 clinical trial 58 IMPROVE HF 58 BARI 2D 58 antihypertensive drugs 58 statin therapy 58 paclitaxel eluting stents 58 randomized double 57 phase IIIb 57 subanalysis 57 meta analysis pooling 57 VADT 57 generalizability 57 Clinical Antipsychotic Trials 57 retrospective cohort study 57 Randomized controlled 57 HIVNET 57 randomized multicenter 57 beta blocker therapy 57 ConclusionThis 57 ExTRACT TIMI 57 longitudinal cohort study 57 warfarin therapy 57 thiazide diuretics 57 CLBP 57 placebo controlled randomized 57 androgen suppression 57 preoperative chemotherapy 57 multicentre randomized 56 fluvastatin 56 adjuvant chemotherapy 56 antiplatelet agents 56 F FDG PET 56 testosterone supplementation 56 nonrandomized studies 56 AVERROES 56 BoNTA 56 dietary intakes 56 rosuvastatin 56 adalimumab 56 Edge STudy 56 Systematic Reviews 56 statins 56 blind randomized 56 dose regimens 56 clinical trials 56 dietary questionnaires 56 dosage regimens 56 tibolone 56 NICE SUGAR 56 longitudinal study 56 observational cohort 56 nonpharmacologic 56 antithrombotic therapy 56 Intervention Trial GAIT 56 Prostate Cancer Prevention 56 studies 56 vitro studies 56 randomized Phase III 56 MERLIN TIMI 56 EURIDIS 56 paricalcitol 56 beta carotene supplementation 56 hypertensive patients 56 multicenter prospective 56 chemoradiotherapy 55 prucalopride 55 SYNTAX trial 55 psychotherapies 55 pre menopausal 55 clinical pharmacology studies 55 AIM HIGH 55 HeFT 55 rosiglitazone 55 NEJM 55 RE LY trial 55 β blockers 55 neoadjuvant 55 Carotid Revascularization Endarterectomy vs. 55 riociguat 55 CALGB 55 eprotirome 55 ACCORD Lipid 55 blind randomized placebo 55 strontium ranelate 55 efficacy 55 Arch Surg 55 atorvastatin Lipitor 55 antiplatelet drugs 55 nulliparous women 55 Doxil ® 55 dose statin therapy 55 prospective observational cohort 55 meta analytic 55 viral kinetic 55 teriflunomide 55 pharmacokinetic studies 55 multicentre study 55 FOSRENOL ® 55 INTERHEART study 55 antiplatelet therapy 55 ACUITY trial 55 Stenting Trial CREST 55 analgesic efficacy 55 double blinded placebo 55 antiepileptics 55 ginkgo biloba extract 55 candesartan 55 bendamustine 55 Health Initiative WHI 55 retrospective observational study 55 CANCIDAS 55 aldosterone antagonists 55 antihypertensive medications 55 NNRTI resistance 55 mycophenolate mofetil 55 clopidogrel pretreatment 55 cardiovascular morbidity 55 idraparinux 55 HYVET 55 chemoradiation 55 prospective randomized placebo 55 psychodynamic psychotherapy 55 placebo controlled Phase 55 CAMMS# 55 Intervention Trial 55 ATACAND 55 oral diclofenac 55 cilostazol 55 aldosterone antagonist 55 fluoxetine Prozac 55 prospectively randomized 55 statin 55 interpersonal psychotherapy 55 pharmacologic treatments 55 glucose lowering 55 TAXUS VI 55 diuretic chlorthalidone 55 ONTARGET 54 generalisability 54 glatiramer acetate 54 reboxetine 54 noninferiority 54 adenotonsillectomy 54 CYPHER R Sirolimus eluting 54 DCCT 54 metastatic RCC 54 oral rivaroxaban 54 journal Ophthalmology 54 routine episiotomy 54 Systematic reviews 54 IQWiG 54 tiotropium 54 HPTN 54 bronchial thermoplasty 54 multicenter placebo controlled 54 deferiprone 54 adjuvant therapies 54 probiotic supplementation 54 Wisconsin Sleep Cohort 54 correlational 54 ARB telmisartan 54 antibiotic prophylaxis 54 LUX Lung 54 GnRH agonists 54 teriparatide 54 statin medications 54 fondaparinux 54 risperidone Risperdal 54 blind placebo controlled 54 HOPE TOO 54 prospectively defined 54 montelukast 54 PLCO trial 54 FOSRENOL R 54 prospective nonrandomized 54 HCV RESPOND 2 54 Phase IIIb study 54 nesiritide 54 HAART regimens 54 nonpregnant women 54 lipid lowering drugs 54 blinded placebo controlled 54 nonoperative 54 dyslipidaemia 54 spinal manipulation 54 Intervention Effectiveness 54 MADIT II 54 tocilizumab 54 dosing cohorts 54 SGAs 54 CHAMPION PCI 54 stone formers 54 rFVIIa 54 methodologic 54 multivariate analyzes 54 multicenter randomized controlled 54 NSABP B 54 lipid lowering agents 54 ACTIVE W 54 valsartan 54 Women Ischemia Syndrome 54 tolvaptan 54 prospective multicenter 54 adjuvant radiotherapy 54 donepezil 54 adjuvant therapy 54 Digital Mammographic Imaging 54 conventional angiography 54 celecoxib 54 HMG CoA reductase inhibitors 54 levosimendan 54 meta regression 53 anastrozole 53 Protelos 53 N acetylcysteine 53 beta carotene supplements 53 dietary modification 53 premenopausal women 53 atherogenic dyslipidemia 53 magnesium supplementation 53 pyridostigmine 53 post hoc 53 observational cohort study 53 chromium supplementation 53 prespecified 53 pegylated liposomal doxorubicin 53 WHI 53 #:# randomization 53 intensive statin therapy 53 oral bisphosphonates 53 viral kinetics 53 NATRECOR R 53 sorafenib Nexavar 53 coadministration 53 STEP BD 53 citalopram 53 pregabalin 53 Cholesterol Levels SPARCL 53 ezetimibe simvastatin 53 zinc supplementation 53 ERSPC 53 antidepressant efficacy 53 folic acid supplementation 53 EVEREST II 53 SCD HeFT 53 RRMS patients 53 paroxetine Paxil 53 composite endpoint 53 journal Rheumatology 53 LDL lowering 53 glucosamine hydrochloride 53 PRoFESS 53 chlorthalidone 53 methodologically rigorous 53 pharmacological therapies 53 postmenopausal 53 liver biopsies 53 efficacy endpoints 53 adenoma recurrence 53 folate supplementation 53 sertraline 53 flutamide 53 tricyclic antidepressants 53 reflux symptoms 53 ticagrelor 53 Intervention Effectiveness CATIE 53 Phase III randomized 53 neuroimaging studies 53 antitumor effect 53 prognostic factors 53 AIR2 Trial 53 regression analyzes 53 randomisation 53 multicenter Phase II 53 prospective randomized multicenter 53 DHA supplementation 53 PREZISTA r 53 CARE HF 53 direct thrombin inhibitors 53 CYP#D# inhibitor 53 protease inhibitor PI 53 #F FDG PET 53 SORT OUT III 53 eptifibatide 53 oncologic outcomes 53 methodological limitations 53 homocysteine lowering 53 CHAMPION PLATFORM 53 commonly prescribed antidepressants 53 SPARCL 53 afatinib 53 Cochrane Library 53 statins cholesterol lowering 53 blind randomized controlled 53 STRIDE PD 53 conjugated equine estrogen 53 RTOG 53 preclinical efficacy 53 oral anticoagulation 52 exploratory endpoints 52 obese postmenopausal 52 tamsulosin 52 IMPROVE IT 52 antibiotic regimens 52 randomized Phase IIb 52 pharmacokinetics PK 52 Diabetologia 52 antiplatelet therapies 52 chest radiographs 52 dose escalation 52 periprocedural MI 52 SPIRIT III 52 CLARITY study 52 infliximab Remicade 52 SPIRIT IV 52 adjuvant radiation 52 temsirolimus 52 breast cancer recurrences 52 #mg dose [001] 52 darunavir ritonavir 52 clinically meaningful 52 metabolic parameters 52 ximelagatran 52 angiotensin receptor blockers 52 posaconazole 52 prospective multicentre 52 urate lowering 52 PRECiSE 52 unfractionated heparin 52 Xelox 52 goserelin 52 dabigatran etexilate 52 Subgroup analysis 52 rosuvastatin Crestor 52 genotypic resistance 52 pharmacokinetic interaction 52 pazopanib 52 secondary efficacy endpoints 52 mg doses 52 corticosteroid injections 52 chemoprevention trials 52 mg Pycnogenol 52 LibiGel Phase III 52 salmeterol fluticasone 52 clomipramine 52 everolimus eluting stents 52 randomized crossover 52 inhaled steroids 52 patients undergoing percutaneous 52 phase IIa 52 logistic regression models 52 pharmacokinetic characteristics 52 pioglitazone 52 multicenter randomized clinical 52 authors conclude 52 nabilone 52 Netherlands Cohort Study 52 PROactive study 52 placebo controlled Phase III 52 KRAS status 52 secretin 52 dose clopidogrel 52 HF ACTION 52 APTIVUS 52 AChE inhibitors 52 GOUT 52 tamoxifen therapy 52 Randomized 52 multicenter clinical 52 nab paclitaxel 52 FOLPI 52 symptomatic VTE 52 MADIT CRT trial 52 abacavir lamivudine 52 macrovascular disease 52 abatacept 52 VTE prophylaxis 52 controlled multicenter 52 clevidipine 52 red clover isoflavones 52 bosentan 52 ancrod 52 eplerenone 52 bezafibrate 52 atherosclerotic renal artery stenosis 52 KRAS variant 52 cardioprotective effect 52 Val MARC 52 inhaled corticosteroids 52 inhaled corticosteroid therapy 52 nonvertebral fractures 52 BCIRG 52 singleton pregnancies 52 RoACTEMRA 52 Clinical Psychiatry 52 bevacizumab Avastin 52 neurodevelopmental outcome 52 neuropsychiatric symptoms 52 psychotherapeutic interventions 52 Polyp Prevention Trial 52 nondiabetic patients 52 phosphate binders 52 APTIVUS r 52 pharmacodynamics 52 hsCRP levels 52 confounding variables 52 ACOSOG Z# 52 sipuleucel T 52 mild gestational diabetes 52 coinvestigators 52 PLCO 52 eculizumab therapy 52 dosing regimens 52 Longitudinal studies 52 Kaplan Meier analysis 52 thiazolidinediones 52 vicriviroc 52 dose escalation clinical 52 Betaferon ® 52 pegylated interferon alfa 2b 52 lanthanum carbonate 52 hemostatic efficacy 52 endarterectomy 52 phase IIb 52 REYATAZ ritonavir 52 multicenter randomized double 52 heartwire 52 pharmacokinetic pharmacodynamic 52 Natural S equol 52 CLA supplementation 52 CAVEATS 52 postmenopausal osteoporotic women 52 Elocalcitol 52 evaluating REVLIMID 52 antihypertensive agents 52 glycemia 52 FDG PET 52 basal bolus regimen 52 telomere lengths 52 intravenous bisphosphonates 52 trastuzumab Herceptin ® 52 DSMB 52 ascending dose 52 postmenopausal hormone therapy 52 DAS# scores 52 refractory CLL 52 factorial design 52 pentoxifylline 52 L thyroxine 52 myocardial infarctions MIs 52 antiepileptic drugs AEDs 52 NSTE ACS 52 antiandrogens 52 mg administered orally 52 ECASS 52 ARCOXIA 52 cholinesterase inhibitors 52 Randomised controlled trials 52 lymphadenectomy 52 pharmacokinetic parameters 52 dose escalation Phase 52 genomewide association study 52 abciximab 52 heavily pretreated patients 52 carotid artery stenting 52 newer antipsychotics 52 NO# [002] 52 thrombolytic therapy 52 aromatase inhibitor therapy 52 dietary antioxidants 52 efficacy endpoint 52 HRQL 52 iniparib 52 irbesartan 52 dose titration 51 PROSTVAC TM 51 cardiovascular mortality 51 Framingham Offspring Study 51 RSD# oral 51 solifenacin 51 peer reviewed 51 ginkgo extract 51 postoperative chemotherapy 51 desvenlafaxine succinate 51 ivabradine 51 nondepressed 51 randomized multicenter Phase III 51 lacosamide 51 aripiprazole Abilify 51 bolus dose 51 ragweed allergic 51 NATRECOR ® 51 pramlintide metreleptin combination 51 Adjuvant chemotherapy 51 Phase 1b trial 51 superficial bladder cancer 51 inhaled nitric oxide 51 study 51 allopurinol 51 lamotrigine 51 Val HeFT 51 #mg/day [001] 51 plasma pharmacokinetics 51 elevated CRP 51 nomograms 51 phase IIb trial 51 anticholinergic drugs 51 LEXIVA r 51 patients undergoing CABG 51 fluoxetine paroxetine 51 hydroxychloroquine 51 chemotherapeutic regimens 51 CHARISMA trial 51 recurrent malignant glioma 51 androgen deprivation 51 olaparib 51 Lancet Neurology 51 postmarketing surveillance 51 pioglitazone Actos 51 telmisartan 51 #mg dose [003] 51 immunohistochemical staining 51 postoperative mortality 51 oral FTY# 51 Teriflunomide 51 renal tumors 51 sunitinib malate 51 unblinded 51 rivaroxaban 51 guggul 51 HIV HCV coinfected 51 Clinical Outcomes Utilizing Revascularization 51 pimecrolimus cream 51 cardioprotective effects 51 Zevalin consolidation 51 Phase III trials 51 colorectal neoplasia 51 QTc prolongation 51 oral Xeloda 51 neratinib 51 SABCS 51 CARDIA 51 NNT = 51 undergone radical prostatectomy 51 XELOX 51 subclinical hypothyroidism 51 leukotriene receptor antagonists 51 hormone therapy HT 51 canakinumab 51 causal inference 51 aspirin clopidogrel 51 trastuzumab emtansine T DM1 51 efavirenz EFV 51 folate intake 51 ACC AHA 51 colorectal liver metastases 51 neurodevelopmental outcomes 51 salmeterol 51 psychodynamic therapy 51 NCCTG N# 51 DASH diet 51 epidemiologic 51 Randomized Clinical Trial 51 Combination therapy 51 clinically meaningful differences 51 cinacalcet 51 urodynamic studies 51 Clinical trials 51 lipid parameters 51 Bonferroni correction 51 logistic regression analyzes 51 resected pancreatic cancer 51 pharmacological approaches 51 nonfatal MI 51 TRITON TIMI 51 lung cancer chemoprevention 51 LPV r 51 Proellex TM 51 journal Lancet Neurology 51 5-FU/LV 51 sentinel node biopsy 51 hemoglobin A1c levels 51 peer reviewed scientific 51 Communities ARIC study 51 ELCAP 51 hydroxyvitamin D levels 51 antithrombotic 51 multicentre prospective 51 acting insulin analogues 51 MMSE scores 51 phase Ib 51 conditional logistic regression 51 Candesartan 51 ADAGIO study 51 Primary endpoints 51 NCT# ClinicalTrials.gov 51 Swedish Mammography Cohort 51 confirmatory clinical 51 Lancet 51 insulin detemir 51 BEACOPP 51 BRIM3 51 Glucosamine Chondroitin Arthritis 51 Observational Study 51 OAB symptoms 51 Phase 2b study 51 Thrombolysis 51 isoflavone supplement 51 sunitinib 51 vildagliptin 51 multidose 51 anti leukemic 51 post menopausal 51 venous thromboembolic disease 51 CYPHER Stent 51 recurrent venous thromboembolism 51 Atherosclerosis MESA 51 bevacizumab 51 TAXUS ATLAS 51 syndromal 51 prospective multicenter study 51 Ovarian PLCO Cancer 51 venlafaxine 51 valsartan Diovan 51 agomelatine 51 mcg doses 51 mg dose 51 Prostate AdenoCarcinoma Treatment 51 ACEIs 51 rt PA 51 blinded randomized placebo controlled 51 imipramine 51 telcagepant 51 aprotinin 51 guanfacine 51 subtrochanteric 51 mammographic density 51 pCR 51 lipid lowering 51 bupropion SR 51 dose aspirin 51 Evaluation WISE 51 univariate 51 adjuvant tamoxifen 51 antithrombotics 51 morphometric vertebral fractures 51 Prostate Lung Colorectal 51 PREVENT IV 51 Relieve Depression 51 NSAIDs 51 PHQ 9 51 antidiabetic drugs 51 Afatinib 51 NEVO ™ 51 candesartan cilexetil 51 serum cholesterol 51 placebos 51 IBS sufferers 51 VFEND 51 low dose cytarabine 51 MADIT CRT 51 zoledronate 51 docetaxel chemotherapy 51 radiographic outcomes 51 placebo controlled multicenter 51 multicenter Phase 51 Systematic Review 51 knee osteoarthritis 51 pharmacological treatments 50 duplex ultrasonography 50 Phase Ib clinical 50 cirrhotic patients 50 TDF FTC 50 unblinding 50 APPROVe 50 multicentre randomized double 50 BOLDER II 50 FROVA 50 number NCT# ClinicalTrials.gov 50 velafermin 50 HRQOL 50 unfractionated heparin UFH 50 EORTC 50 tolerability pharmacokinetics 50 hemodialysis patients 50 BYSTOLIC 50 bexarotene 50 supplementation 50 revascularization procedures 50 letrozole 50 carotid artery stenting CAS 50 cognitive domains 50 dabigatran 50 multicenter randomized placebo controlled 50 blinded randomized 50 DHEA supplementation 50 Kaplan Meier curves 50 valvulopathy 50 tipranavir 50 DMARDS 50 pravastatin therapy 50 clazosentan 50 metformin monotherapy 50 elective PCI 50 perinatal outcomes 50 COREG 50 psychometric properties 50 tolerability profiles 50 APPRAISE 50 multicenter multinational 50 Percutaneous Coronary Intervention 50 prazosin 50 knee OA 50 antiarrhythmic drug 50 biologic plausibility 50 newer atypical antipsychotics 50 empiric 50 comparator arm 50 CYP#D# inhibitors 50 symptomatic BPH 50 co trimoxazole 50 myocardial infarctions 50 GFT# 50 neoadjuvant treatment 50 nephron sparing surgery 50 iPrEx study 50 Health Initiative Observational 50 thromboembolic 50 ACTEMRA TM 50 Multiple logistic regression 50 RG# ITMN 50 statistically significant differences 50 susceptibility loci 50 plain radiographs 50 Atacand 50 NHANES III 50 lowering LDL cholesterol 50 vitro experiments 50 sotalol 50 Multiethnic Study 50 L lysine 50 Avandia Actos 50 ß blockers 50 d4T 50 QVAR R 50 insulin glargine 50 MoxDuo TM IR 50 interferon alfa 2b 50 salsalate 50 pramipexole 50 metastatic HRPC 50 anakinra 50 atazanavir 50 Dietary Modification Trial 50 aripiprazole 50 acamprosate 50 LUTS 50 BENICAR HCT 50 concomitant medications 50 NOXAFIL 50 ABSORB trial 50 azacitidine 50 MEDLINE 50 mcg dose 50 cardio protective 50 ABCSG 50 acrylamide intake 50 cerebral microbleeds 50 dosing schedules 50 Bivalirudin 50 REVIVE TA 50 CAM modalities 50 polyarticular 50 endometrial hyperplasia 50 ziprasidone 50 pharmacologic intervention 50 pelvic lymphadenectomy 50 lipid lowering medications 50 Randomized clinical trials 50 peginterferon alfa 2a 50 bowel capsule endoscopy 50 coronary revascularization 50 Epidemiologic studies 50 phase IIb study 50 BEXXAR Therapeutic Regimen 50 postoperative complications 50 angiographic outcomes 50 Celecoxib APC trial 50 efficacy tolerability 50 DMARD 50 maximally tolerated dose 50 androgen ablation 50 Multi Ethnic Study 50 ASCEND HF 50 methodologically sound 50 dose proportionality 50 actigraphy 50 relapsed MM 50 ritonavir boosted lopinavir 50 intravesical therapy 50 Perforomist Inhalation Solution 50 enzastaurin 50 DPNP 50 virological response 50 angiotensin II receptor blockers 50 chromium picolinate supplementation 50 AVOREN 50 olmesartan 50 Celecoxib 50 virologically 50 CTEPH 50 TAXUS ARRIVE 50 methotrexate monotherapy 50 dietary supplementation 50 rEEG 50 COPAXONE R 50 sildenafil Viagra 50 biologic DMARDs 50 oral prednisolone 50 hypertensives 50 hormone therapy estrogen 50 statistically nonsignificant 50 ENESTnd 50 Meta Analysis 50 pharmacotherapies 50 bivariate analyzes 50 paroxysmal AF 50 anti arrhythmic drug 50 ACCOMPLISH 50 carvedilol 50 non inferiority 50 FOLFOX 50 Vertos II 50 zonisamide 50 Remifemin 50 ritonavir boosted 50 Multicenter 50 venlafaxine Effexor 50 MAS XR 50 virologic responses 50 GISSI 50 Phase 2a trial 50 Femara letrozole 50 Liver biopsy 50 ToGA 50 phase IIa clinical 50 pharmacokinetic PK 50 antiangiogenic agents 50 pimecrolimus 50 anticoagulation 50 platelet inhibition 50 clopidogrel Plavix 50 treatment naïve genotype 50 antiandrogen 50 NeuroStar TMS Therapy 50 CTAP# Capsules 50 LNG IUS 50 Rigorous scientific 50 HNSCC 50 clopidogrel 50 urolithiasis 50 dietary intake 50 Medicine NEJM 50 multivitamin supplements 50 STICH trial 50 Celebrex celecoxib 50 ENDEAVOR clinical 50 Randomized Controlled Trial 50 glucocorticoid induced osteoporosis 50 generalisable 50 febuxostat 50 osteoarthritis sufferers 50 Truvada tablets 50 PRIMO CABG 50 caspofungin 50 ARIXTRA 50 azathioprine 50 prespecified secondary 50 TMC# C# 50 vitamin D supplements 50 NEVO RES 50 Randomised 50 inhaled anticholinergics 50 randomized multicentre 50 prasugrel Effient 50 umol L 50 biochemical recurrence 50 antidepressant therapy 50 glycoprotein IIb IIIa inhibitors 50 homocysteine concentrations 50 mg BID dose 50 CATIE 50 selective serotonin reuptake inhibitor 50 vitamin supplementation 50 Raloxifene Evaluation MORE 50 pitavastatin 50 dietary interventions 50 Peg IFN 50 FASLODEX 50 Pycnogenol ® 50 ascending doses 50 behavioral interventions 50 convergent validity 50 MBCT 50 divalproex sodium 50 nelfinavir 50 histologically proven 50 perioperatively 50 MICARDIS ® 50 CARDIA study 50 non selective NSAIDs 50 clinically meaningful improvements 50 BJU International 50 coinfected patients 50 clinicopathological 50 prostate cancer PCa 50 daunorubicin 50 RECORD1 50 glitazones 50 anticoagulation therapy 50 underwent CABG 50 arzoxifene 50 masked placebo controlled 50 RE SURGE 50 SAMe 50 dexmedetomidine